For patients facing serious, life-threatening, or rare medical conditions, waiting for a medicine to complete the traditional regulatory approval process is often not an option. When no satisfactory approved treatment exists or participation in a clinical trial is not feasible, Expanded Access Programs (EAPs) provide a vital pathway to potentially beneficial investigational therapies. At Iberimed S.A., we specialize in facilitating Expanded Access Programs that connect patients with promising treatments while ensuring full regulatory compliance, ethical oversight, and operational excellence throughout the process.

Expanded Access Programs serve as a critical bridge between pharmaceutical innovation and patient care. They allow eligible patients to receive investigational medicines outside of clinical trials under carefully controlled regulatory frameworks established by health authorities. Our experienced team works alongside pharmaceutical manufacturers, physicians, hospitals, regulatory agencies, and healthcare institutions to coordinate every aspect of these programs, ensuring patients gain timely access to therapies while maintaining the highest standards of safety and accountability.

Every Expanded Access request carries profound significance. Behind every application is a patient, a physician, and a family searching for hope when conventional treatment options have been exhausted. Iberimed S.A. approaches every case with urgency, compassion, and meticulous attention to detail, recognizing that our role extends beyond logistics to supporting better patient outcomes during some of the most critical moments in healthcare.